New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity

Eli Lilly's experimental drug, retatrutide, helped Type 2 diabetes patients lose 20.8% of their body weight in an 80-week trial. The highest dose group saw an average weight reduction of 49.6 pounds. The drug also improved blood sugar control, with 40% of participants on the two highest doses achieving normal blood sugar levels. The results were presented at the European Association for the Study of Diabetes meeting and published in The Lancet.

Eli Lilly reported Phase 3b data showing combined Taltz and Zepbound treatment led to broader changes in psoriasis-related, immune, and metabolic biomarkers compared to Taltz alone. The study involved adults with psoriasis and obesity or overweight. LLY closed at $1,169.60, down 1.61%, and is down 0.51% in pre-market trading.

Eli Lilly (NYSE:LLY) presented data from its TOGETHER-PsO Phase 3b trial, showing broader biomarker responses with the combination of Taltz and Zepbound versus Taltz alone in patients with psoriasis and obesity. The 52-week study enrolled 274 participants, with primary endpoints assessing skin clearance and weight reduction.

Eli Lilly presented Phase 3b data from the TOGETHER-PsO study, showing that Taltz (ixekizumab) and Zepbound (tirzepatide) together led to broader biomarker changes in psoriasis and obesity patients compared to Taltz alone. The combination therapy showed greater reductions in inflammatory immune activity and improved psoriasis-specific markers by Week 12. The study involved 274 participants and evaluated the efficacy and safety of the combination treatment over 52 weeks.

A phase 3b trial of lebrikizumab (Ebglyss) showed over 50% of patients with moderate-to-severe hand and foot eczema achieved clear or almost clear skin. Significant reductions in itch and pain were reported, with 76.7% of patients satisfied with skin clearance. Lebrikizumab, approved for atopic dermatitis, is developed by Eli Lilly and Almirall in Europe.

Cantor Fitzgerald raised its price target for Eli Lilly (NYSE:LLY) to $1,440, citing strong demand trends and potential tailwinds from new products. The stock trades at $1,189 with a market cap of $1.06 trillion. Analysts note pricing headwinds but highlight a PEG ratio of 0.42 and 49.6% revenue growth. Recent FDA approvals and positive analyst ratings also support the stock.